查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566982

病毒载体和质体DNA 製造市场：按载体类型、工作流程、应用和最终用户：2024-2033 年全球机会分析和产业预测

Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus , Lentivirus, Plasmids, Others), By Workflow By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

病毒载体及质体DNA製造市场

2023年病毒载体及质体DNA製造市值为53亿美元，预估2024年至2033年复合年增长率为20.4%，至2033年达340亿美元。

病毒载体和质体DNA 是基因工程的重要组成部分，可用于多种目的，包括基因治疗和疫苗生产。病毒载体是一种分子载体，用于透过基因表现或将遗传物质整合到细胞 DNA 中将遗传讯息转移到细胞中。质体DNA 是细菌中发现的染色体外环状 DNA。用作基因克隆和基因治疗的载体。病毒载体和质体DNA 可以使用多种方法生产，包括细胞培养系统、精製过程和细菌发酵。

遗传疾病的日益普及和技术进步正在促进基因治疗的实施，从而推动病毒载体和质体DNA 製造市场的成长。此外，由于政府和食品药物管理局等监管机构的投资激增和支持，研发活动的增加正在推动对病毒载体和质体DNA 製造的需求。使用人工智慧和机器学习演算法来提高製造的可扩展性的趋势日益明显。演算法有助于确定精确的要求和理想条件，以最大限度地提高载体和质体的产量。

然而，在製造过程中防止污染是一个挑战，因为一个小异物可能会毁掉整个生产批次。这项挑战极大地限制了病毒载体和质体DNA 製造市场的成长。此外，製造所需设备的采购和维护成本非常昂贵，限制了小型企业和研究机构的投资并阻碍了市场成长。此外，世界各地监管程序的差异限制了载体和质体在某些地区的效用。例如，欧洲指南要求在製造的各个阶段遵守当前的良好製造规范。相较之下，美国食品药物管理局(FDA) 允许某些材料和所有相关属性或验收标准在产品开发的第一阶段保持未知。

分部审查

病毒载体和质体DNA 製造市场分为载体类型、工作流程、应用、最终用户和区域。依载体类型分为腺病毒、逆转录病毒、腺结合病毒（AAV）、慢病毒、质体等。工作流程分为上游製造和下游製造。依用途分为反义&RNAi疗法、反义&RNAi疗法、细胞疗法、疫苗疗法和研究用途。依最终用户分为製药/生物製药公司和研究机构。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按载体类型划分，腺结合病毒(AAV) 细分市场在 2023 年占据主导地位。

从工作流程来看，下游製造领域在2023年占据了较高的市场占有率。

从应用来看，2023年疫苗接种领域在市场中占有较高份额。

按最终用户划分，研究机构细分市场将在 2023 年获得较高份额。

按地区划分，北美地区 2023 年收益最高。

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章病毒载体与质体DNA 製造市场：依载体型

  • 市场概况
  • 腺病毒
  • 逆转录病毒
  • 腺相关病毒（AAV）
  • 慢病毒
  • 质体
  • 其他的

第五章病毒载体与质体DNA 製造市场：依工作流程

  • 市场概况
  • 上游製造
  • 下游製造

第六章病毒载体与质体DNA 製造市场：依应用分类

  • 市场概况
  • 反义RNAi疗法
  • 反义RNAi疗法
  • 细胞疗法
  • 疫苗治疗
  • 研究用途

第七章 病毒载体与质体DNA 製造市场：依最终使用者分类

  • 市场概况
  • 医药生物製药公司
  • 研究所

第八章病毒载体和质体DNA 製造市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国病毒载体及质体DNA製造市场
    • 加拿大病毒载体与质体DNA製造市场
    • 墨西哥病毒载体与质体DNA製造市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国病毒载体与质体DNA製造市场
    • 法国病毒载体与质体DNA製造市场
    • 英国病毒载体与质体DNA製造市场
    • 义大利病毒载体及质体DNA製造市场
    • 西班牙病毒载体与质体DNA製造市场
    • 其他欧洲病毒载体及质体DNA 製造市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本病毒载体及质体DNA製造市场
    • 中国病毒载体与质体DNA製造市场
    • 澳洲病毒载体及质体DNA製造市场
    • 印度的病毒载体与质体DNA製造市场
    • 韩国病毒载体及质体DNA製造市场
    • 其他亚太病毒载体及质体DNA 製造市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西病毒载体及质体DNA製造市场
    • 沙乌地阿拉伯的病毒载体和质体DNA製造市场
    • 南非的病毒载体与质体DNA製造市场
    • 其他拉丁美洲/中东/非洲病毒载体和质体DNA 製造市场

第9章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第十章 公司简介

  • Merck KGaA
  • Lonza Group AG
  • FUJIFILM Corporation
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent Inc.
  • WuXi Biologics.
  • TakarBio Inc
  • Waisman Biomanufacturing, LLC
  • Genezen Laboratories
简介目录
Product Code: A324540

Viral Vectors and Plasmid DNA Manufacturing Market

The viral vectors and plasmid DNA manufacturing market was valued at $5.3 billion in 2023 and is projected to reach $34.0 billion by 2033, growing at a CAGR of 20.4% from 2024 to 2033.

Viral vector and plasmid DNA are the crucial components of genetic engineering, utilized for diverse purposes such as gene therapy and vaccine production. A viral vector is a form of molecular vehicle used to transfer genetic information to the cells either through gene expression or integration of genetic material into the cell's DNA. Plasmid DNA is an extrachromosomal circular piece of DNA present in bacteria. It serves as a vector for gene cloning, and gene therapy. The manufacturing of viral vectors and plasmid DNA is accomplished through various methods such as cell culture systems, purification processes, or bacterial fermentation.

Increase in the prevalence of genetic disorders and advancements in technology have facilitated the execution of gene therapies, thereby driving the growth of the viral vectors and plasmid DNA manufacturing market. In addition, rise in R&D activities due to surge in investments & support from government and regulatory agencies such as the Food and Drug administration is boosting the demand for the manufacturing for viral vectors and plasmid DNA. To enhance the scalability of production, the trend of using AI and ML algorithms is gaining prominence. The algorithm helps in identifying the precise requirements and ideal conditions to maximize the production of vectors and plasmid.

However, preventing contamination during manufacturing is challenging as a tiny foreign particle is capable of spoiling the entire production batch. This challenge significantly restrains the growth of the viral vectors and plasmid DNA manufacturing market. In addition, the procurement and maintenance of the equipment required for production is highly expensive, which limits several small-scale firms and laboratories from investing, hence hampering the market growth. Moreover, discrepancies in the regulatory process across the globe restrict the utility of the vectors and plasmid in certain regions. For instance, the European guidelines have mandated the compliance of products with the current good manufacturing practices standards at all stages of production. Contrarily, as per the U.S. Food and Drug Administration, it is acceptable that some materials and all relevant attributes or acceptance criteria remain unknown at stage 1 of product development.

Segment Review

The viral vectors and plasmid DNA manufacturing market is segmented into vector type, workflow, application, end user, and region. On the basis of vector type, the market is divided into adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Depending on workflow, it is bifurcated into upstream manufacturing and downstream manufacturing. As per application, it is classified into antisense & RNAi therapy, antisense & RNAi therapy, cell therapy, vaccinology, and research applications. According to end user, it is categorized into pharmaceutical & biopharmaceutical companies and research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of vector type, the adeno-associated virus (AAV) segment dominated the market in 2023.

Depending on workflow, the downstream manufacturing segment accounted for a high market share in 2023.

As per application, the vaccinology segment acquired a high stake in the market in 2023.

According to end user, the research institutes segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global viral vectors and plasmid DNA manufacturing market include Merck KGaA, Lonza Group AG, FUJIFILM Corporation, thermo fisher scientific, Cobra Biologics, Catalent Inc., WuXi Biologics., TakarBio Inc, Waisman Biomanufacturing, LLC, and Genezen laboratories. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Vector Type

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

By Workflow

  • Upstream Manufacturing
  • Downstream Manufacturing

By Application

  • Antisense RNAi Therapy
  • Antisense RNAi Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

By End User

  • Pharmaceutical Biopharmaceutical Companies
  • Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Merck KGaA
    • Lonza Group AG
    • FUJIFILM Corporation
    • Thermo Fisher Scientific Inc.
    • Cobra Biologics
    • Catalent Inc.
    • WuXi Biologics.
    • TakarBio Inc
    • Waisman Biomanufacturing, LLC
    • Genezen laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Vector Type
  • 4.2. Adenovirus
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Retrovirus
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Adeno-Associated Virus (AAV)
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Lentivirus
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Plasmids
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country
  • 4.7. Others
    • 4.7.1. Key Market Trends, Growth Factors and Opportunities
    • 4.7.2. Market Size and Forecast, By Region
    • 4.7.3. Market Share Analysis, By Country

CHAPTER 5: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Workflow
  • 5.2. Upstream Manufacturing
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Downstream Manufacturing
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Application
  • 6.2. Antisense RNAi Therapy
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Antisense RNAi Therapy
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Cell Therapy
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Vaccinology
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country
  • 6.6. Research Applications
    • 6.6.1. Key Market Trends, Growth Factors and Opportunities
    • 6.6.2. Market Size and Forecast, By Region
    • 6.6.3. Market Share Analysis, By Country

CHAPTER 7: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By End User
  • 7.2. Pharmaceutical Biopharmaceutical Companies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Research Institutes
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country

CHAPTER 8: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Vector Type
    • 8.2.3. Market Size and Forecast, By Workflow
    • 8.2.4. Market Size and Forecast, By Application
    • 8.2.5. Market Size and Forecast, By End User
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.2.7.1. Market Size and Forecast, By Vector Type
      • 8.2.7.2. Market Size and Forecast, By Workflow
      • 8.2.7.3. Market Size and Forecast, By Application
      • 8.2.7.4. Market Size and Forecast, By End User
    • 8.2.8. Canada Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.2.8.1. Market Size and Forecast, By Vector Type
      • 8.2.8.2. Market Size and Forecast, By Workflow
      • 8.2.8.3. Market Size and Forecast, By Application
      • 8.2.8.4. Market Size and Forecast, By End User
    • 8.2.9. Mexico Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.2.9.1. Market Size and Forecast, By Vector Type
      • 8.2.9.2. Market Size and Forecast, By Workflow
      • 8.2.9.3. Market Size and Forecast, By Application
      • 8.2.9.4. Market Size and Forecast, By End User
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Vector Type
    • 8.3.3. Market Size and Forecast, By Workflow
    • 8.3.4. Market Size and Forecast, By Application
    • 8.3.5. Market Size and Forecast, By End User
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.7.1. Market Size and Forecast, By Vector Type
      • 8.3.7.2. Market Size and Forecast, By Workflow
      • 8.3.7.3. Market Size and Forecast, By Application
      • 8.3.7.4. Market Size and Forecast, By End User
    • 8.3.8. France Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.8.1. Market Size and Forecast, By Vector Type
      • 8.3.8.2. Market Size and Forecast, By Workflow
      • 8.3.8.3. Market Size and Forecast, By Application
      • 8.3.8.4. Market Size and Forecast, By End User
    • 8.3.9. UK Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.9.1. Market Size and Forecast, By Vector Type
      • 8.3.9.2. Market Size and Forecast, By Workflow
      • 8.3.9.3. Market Size and Forecast, By Application
      • 8.3.9.4. Market Size and Forecast, By End User
    • 8.3.10. Italy Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.10.1. Market Size and Forecast, By Vector Type
      • 8.3.10.2. Market Size and Forecast, By Workflow
      • 8.3.10.3. Market Size and Forecast, By Application
      • 8.3.10.4. Market Size and Forecast, By End User
    • 8.3.11. Spain Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.11.1. Market Size and Forecast, By Vector Type
      • 8.3.11.2. Market Size and Forecast, By Workflow
      • 8.3.11.3. Market Size and Forecast, By Application
      • 8.3.11.4. Market Size and Forecast, By End User
    • 8.3.12. Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.12.1. Market Size and Forecast, By Vector Type
      • 8.3.12.2. Market Size and Forecast, By Workflow
      • 8.3.12.3. Market Size and Forecast, By Application
      • 8.3.12.4. Market Size and Forecast, By End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Vector Type
    • 8.4.3. Market Size and Forecast, By Workflow
    • 8.4.4. Market Size and Forecast, By Application
    • 8.4.5. Market Size and Forecast, By End User
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.7.1. Market Size and Forecast, By Vector Type
      • 8.4.7.2. Market Size and Forecast, By Workflow
      • 8.4.7.3. Market Size and Forecast, By Application
      • 8.4.7.4. Market Size and Forecast, By End User
    • 8.4.8. China Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.8.1. Market Size and Forecast, By Vector Type
      • 8.4.8.2. Market Size and Forecast, By Workflow
      • 8.4.8.3. Market Size and Forecast, By Application
      • 8.4.8.4. Market Size and Forecast, By End User
    • 8.4.9. Australia Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.9.1. Market Size and Forecast, By Vector Type
      • 8.4.9.2. Market Size and Forecast, By Workflow
      • 8.4.9.3. Market Size and Forecast, By Application
      • 8.4.9.4. Market Size and Forecast, By End User
    • 8.4.10. India Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.10.1. Market Size and Forecast, By Vector Type
      • 8.4.10.2. Market Size and Forecast, By Workflow
      • 8.4.10.3. Market Size and Forecast, By Application
      • 8.4.10.4. Market Size and Forecast, By End User
    • 8.4.11. South Korea Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.11.1. Market Size and Forecast, By Vector Type
      • 8.4.11.2. Market Size and Forecast, By Workflow
      • 8.4.11.3. Market Size and Forecast, By Application
      • 8.4.11.4. Market Size and Forecast, By End User
    • 8.4.12. Rest of Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.12.1. Market Size and Forecast, By Vector Type
      • 8.4.12.2. Market Size and Forecast, By Workflow
      • 8.4.12.3. Market Size and Forecast, By Application
      • 8.4.12.4. Market Size and Forecast, By End User
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Vector Type
    • 8.5.3. Market Size and Forecast, By Workflow
    • 8.5.4. Market Size and Forecast, By Application
    • 8.5.5. Market Size and Forecast, By End User
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.7.1. Market Size and Forecast, By Vector Type
      • 8.5.7.2. Market Size and Forecast, By Workflow
      • 8.5.7.3. Market Size and Forecast, By Application
      • 8.5.7.4. Market Size and Forecast, By End User
    • 8.5.8. Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.8.1. Market Size and Forecast, By Vector Type
      • 8.5.8.2. Market Size and Forecast, By Workflow
      • 8.5.8.3. Market Size and Forecast, By Application
      • 8.5.8.4. Market Size and Forecast, By End User
    • 8.5.9. South Africa Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.9.1. Market Size and Forecast, By Vector Type
      • 8.5.9.2. Market Size and Forecast, By Workflow
      • 8.5.9.3. Market Size and Forecast, By Application
      • 8.5.9.4. Market Size and Forecast, By End User
    • 8.5.10. Rest of LAMEA Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.10.1. Market Size and Forecast, By Vector Type
      • 8.5.10.2. Market Size and Forecast, By Workflow
      • 8.5.10.3. Market Size and Forecast, By Application
      • 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Merck KGaA
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Lonza Group AG
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. FUJIFILM Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Thermo Fisher Scientific
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Cobra Biologics
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Catalent Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. WuXi Biologics.
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. TakarBio Inc
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Waisman Biomanufacturing, LLC
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Genezen Laboratories
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments